RT Journal Article
SR Electronic
T1 A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.05.20206938
DO 10.1101/2020.10.05.20206938
A1 Maile T. Phillips
A1 James E. Meiring
A1 Merryn Voysey
A1 Joshua L. Warren
A1 Stephen Baker
A1 Buddha Basnyat
A1 John D. Clemens
A1 Christiane Dolecek
A1 Sarah J. Dunstan
A1 Gordon Dougan
A1 Melita A. Gordon
A1 Robert S. Heyderman
A1 Kathryn E. Holt
A1 Firdausi Qadri
A1 Andrew J. Pollard
A1 Virginia E. Pitzer
A1 the STRATAA Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2020.10.05.20206938.abstract
AB Decisions about typhoid fever prevention and control are based on estimates of typhoid incidence and their uncertainty. Lack of specific clinical diagnostic criteria, poorly sensitive diagnostic tests, and scarcity of accurate and complete datasets contribute to difficulties in calculating age-specific population-level typhoid incidence. Using data from the Strategic Alliance across Africa & Asia (STRATAA) programme, we integrated demographic censuses, healthcare utilization surveys, facility-based surveillance, and serological surveillance from Malawi, Nepal, and Bangladesh to account for under-detection of cases. We developed a Bayesian approach that adjusts the count of reported blood-culture-positive cases for blood culture detection, blood culture collection, and healthcare seeking—and how these factors vary by age—while combining information from prior published studies. We validated the model using simulated data. The ratio of observed to adjusted incidence rates was 7.7 (95% credible interval (CrI): 6.0-12.4) in Malawi, 14.4 (95% CrI: 9.3-24.9) in Nepal, and 7.0 (95% CrI: 5.6-9.2) in Bangladesh. The probability of blood culture collection led to the largest adjustment in Malawi, while the probability of seeking healthcare contributed the most in Nepal and Bangladesh; adjustment factors varied by age. Adjusted incidence rates were within the seroincidence rate limits of typhoid infection. Estimates of blood-culture-confirmed typhoid fever without these adjustments results in considerable underestimation of the true incidence of typhoid fever. Our approach allows each phase of the reporting process to be synthesized to estimate the adjusted incidence of typhoid fever while correctly characterizing uncertainty, which can inform decision-making for typhoid prevention and control.Competing Interest StatementVEP is a member of the World Health Organization's (WHO) Immunization and Vaccine-related Implementation Research Advisory Committee. AJP chairs the UK Department of Health's (DoH) Joint Committee on Vaccination and Immunisation (JCVI) and the European Medicines Agency Scientific Advisory Group on Vaccines and is a member of the World Health Organization's (WHO) Strategic Advisory Group of Experts. The views expressed in this manuscript are those of the authors and do not necessarily reflect the views of the JCVI, the DoH, or the WHO.Funding StatementVSP is supported by the Wellcome Trust Strategic Award (106158/Z/14/Z) and the Bill and Melinda Gates Foundation (OPP1141321). RSH is supported by the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal Pathogens using UK aid from the UK Government. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee approval for a joint study protocol was obtained within each country (Malawi, Nepal, and Bangladesh) as well as from the Oxford Tropical Research Ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to patient privacy, the data for this analysis cannot be shared publicly. However, the R code used for the model and the simulated data are available on: https://github.com/mailephillips/adjusted-typhoid-incidence. https://github.com/mailephillips/adjusted-typhoid-incidence